CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 47 enrolled
Drug / intervention
Sulfur Hexafluoride Microspheresdrug
Likely dose
Sulfur Hexafluoride Microspheres 2.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03652636
NCT03652636Phase 4Completed
CompareCT.gov

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Indiana University·interventional·Posted Aug 29, 2018·Updated Oct 2, 2024

In Brief

A Phase 4 clinical trial evaluating Sulfur Hexafluoride Microspheres for Hepatic Disease. Completed, enrolled 47 participants across 1 site.

Detailed Summary

In patients with hepatic lesions, to evaluate the efficacy of contrast enhanced ultrasound compared to MRI in differentiating focal nodular hyperplasia and hepatic adenoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartAug 5, 2019
Primary CompletionJul 21, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.8 years ago

Interventions

Sulfur Hexafluoride Microspheresdrug

2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization